19 results on '"Neelakantan, Pratap"'
Search Results
2. Optimisation of CML therapy
3. Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
4. Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects
5. Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines
6. A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
7. Breast cancer metastasizing to the tongue
8. Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
9. PB1886: REAL WORLD EXPERIENCE OF VENETOCLAX‐AZACYTIDINE COMBINATION IN FRAIL ELDERLY PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY.
10. Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy.
11. Combined IL‐6 and JAK/STAT inhibition therapy in COVID‐19‐related sHLH, potential game changer.
12. Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience.
13. Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK
14. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
15. Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?
16. Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR–ABL1.
17. The management of myelofibrosis: A British Society for Haematology Guideline.
18. The transformative journey of chronic myeloid leukemia.
19. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.